GoAI
Get started
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG

CRSP

NASDAQHealthcareBiotechnology

Open in GoAI

Regular session

$57.31

−$2.19 · -3.68%

Aug 24, 12:29 PM ET

CRSP company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

2

Overpriced

Momentum

48

Neutral

Sentiment

68

Bullish

Risk resilience

39

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.

Industry
Biotechnology
Sector
Healthcare
Headquarters
CH
CEO
Samarth Kulkarni
Listed since
Oct 19, 2016
Employees
393

Market position

Day range

Current $57.31

52-week range

Current $57.31

Open
$58.61
Previous close
$59.50
Volume
595.74K
0.35× average
Average volume
1.72M
Average daily volume
Market cap
5.53B USD
Beta
1.74
Market reference 1
50-day average
$52.7686
+8.61% above average
200-day average
$53.0826
+7.96% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
4.76B USD
P/E (TTM)
-12.04×
P/B (TTM)
3.17×
P/S (TTM)
412.74×
EV / EBITDA
-8.51×
Earnings yield
-12.33%
Free cash flow yield
-7.34%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-1534.39%
Operating margin
-3971.53%
Net margin
-3368.72%
Return on equity
-30.26%
Return on assets
-25.67%
Return on invested capital
-26.62%

Financial health

Debt / equity
0.45×
Current ratio
13.32×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends15537%-46256%-108050%-169843%Gross margin, FY2021: 88.92%Gross margin, FY2022: -25186.70%Gross margin, FY2023: 64.80%Gross margin, FY2024: -215.00%Gross margin, FY2025: -6537.01%Operating margin, FY2021: 40.91%Operating margin, FY2022: -154394.72%Operating margin, FY2023: -60.15%Operating margin, FY2024: -1333.05%Operating margin, FY2025: -16191.40%Net margin, FY2021: 41.36%Net margin, FY2022: -149122.71%Net margin, FY2023: -41.52%Net margin, FY2024: -1046.43%Net margin, FY2025: -16569.77%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 88.92%. Gross margin FY2022 -25186.70%. Gross margin FY2023 64.80%. Gross margin FY2024 -215.00%. Gross margin FY2025 -6537.01%. Operating margin FY2021 40.91%. Operating margin FY2022 -154394.72%. Operating margin FY2023 -60.15%. Operating margin FY2024 -1333.05%. Operating margin FY2025 -16191.40%. Net margin FY2021 41.36%. Net margin FY2022 -149122.71%. Net margin FY2023 -41.52%. Net margin FY2024 -1046.43%. Net margin FY2025 -16569.77%.

Income trends

Revenue

3.51M USD-89.97%

Operating income

−568.32M USD-21.81%

Net income

−581.6M USD-58.80%
Income trends across reported periods1.07B USD437.21M USD−197.29M USD−831.79M USDRevenue, FY2021: 913.08M USDRevenue, FY2022: 436K USDRevenue, FY2023: 370M USDRevenue, FY2024: 35M USDRevenue, FY2025: 3.51M USDOperating income, FY2021: 373.53M USDOperating income, FY2022: −673.16M USDOperating income, FY2023: −222.54M USDOperating income, FY2024: −466.57M USDOperating income, FY2025: −568.32M USDNet income, FY2021: 377.66M USDNet income, FY2022: −650.18M USDNet income, FY2023: −153.61M USDNet income, FY2024: −366.25M USDNet income, FY2025: −581.6M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 913.08M USD. Revenue FY2022 436K USD. Revenue FY2023 370M USD. Revenue FY2024 35M USD. Revenue FY2025 3.51M USD. Operating income FY2021 373.53M USD. Operating income FY2022 −673.16M USD. Operating income FY2023 −222.54M USD. Operating income FY2024 −466.57M USD. Operating income FY2025 −568.32M USD. Net income FY2021 377.66M USD. Net income FY2022 −650.18M USD. Net income FY2023 −153.61M USD. Net income FY2024 −366.25M USD. Net income FY2025 −581.6M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue3.51M USD35M USD370M USD436K USD913.08M USD
Cost of goods sold232.96M USD110.25M USD130.25M USD110.25M USD101.18M USD
Gross profit−229.45M USD−75.25M USD239.75M USD−109.81M USD811.9M USD
Research and development265.33M USD320.65M USD387.33M USD461.65M USD340.57M USD
Selling, general, and administrative73.54M USD72.98M USD76.16M USD102.46M USD99.69M USD
Operating expenses338.87M USD391.32M USD462.29M USD563.35M USD438.38M USD
Depreciation and amortization19.48M USD19.26M USD19.84M USD24.17M USD17.95M USD
Operating income−568.32M USD−466.57M USD−222.54M USD−673.16M USD373.53M USD
Net income−581.6M USD−366.25M USD−153.61M USD−650.18M USD377.66M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
+152.23%
11 comparable reports
Latest EPS result
-0.94
Estimate -1.19 · Beat by 21.01%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.37-1.1-1.83-2.56Q1 '25BeatQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 11, 2025: actual -0.44, estimate -1.15, surprise +61.74%, Beat. Q2 2025, reported May 6, 2025: actual -1.58, estimate -1.27, surprise -24.41%, Miss. Q3 2025, reported Aug 5, 2025: actual -2.4, estimate -1.47, surprise -63.27%, Miss. Q4 2025, reported Nov 10, 2025: actual -1.17, estimate -1.26, surprise +7.14%, Beat. Q1 2026, reported Feb 12, 2026: actual -1.37, estimate -1.15, surprise -19.13%, Miss. Q2 2026, reported May 4, 2026: actual -1.28, estimate -1.19, surprise -7.60%, Miss. Q3 2026, reported Aug 3, 2026: actual -0.94, estimate -1.19, surprise +21.01%, Beat. Q4 2026, reported Nov 9, 2026: actual —, estimate -1.06, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates37.73M25.4M13.07M734.4KQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 11, 2025: actual 35M USD, estimate 8.06M USD, surprise +334.51%, Beat. Q2 2025, reported May 6, 2025: actual 865K USD, estimate 5.96M USD, surprise -85.50%, Miss. Q3 2025, reported Aug 5, 2025: actual 892K USD, estimate 6.14M USD, surprise -85.47%, Miss. Q4 2025, reported Nov 10, 2025: actual 889K USD, estimate 9.12M USD, surprise -90.25%, Miss. Q1 2026, reported Feb 12, 2026: actual 864K USD, estimate 4.72M USD, surprise -81.69%, Miss. Q2 2026, reported May 4, 2026: actual 1.46M USD, estimate 6.06M USD, surprise -75.96%, Miss. Q3 2026, reported Aug 3, 2026: actual 10.18M USD, estimate 7.45M USD, surprise +36.69%, Beat. Q4 2026, reported Nov 9, 2026: actual —, estimate 14.84M USD, surprise —, Comparison unavailable.

CRSP peers

Amgen Inc. logo

AMGN

Amgen Inc.

$441.01

+0.38%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.17

+0.03%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$547.77

-0.05%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$376.6

-0.58%

Sanofi logo

SNY

Sanofi

$45.602

-0.54%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$825.38

-1.04%

ETFs holding CRSP

Funds reporting this stock among their holdings, ordered by reported position size.

ARK Innovation ETF logoARK Innovation ETFARKK
Market value
321.25M
Weight
4.84%
AUM
5.56B USD
Expense ratio
0.75%
Price / 1D
$85.03-1.36%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
139.9M
Weight
0.17%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$298.35-0.54%
ARK Genomic Revolution ETF logoARK Genomic Revolution ETFARKG
Market value
126.31M
Weight
6.09%
AUM
1.56B USD
Expense ratio
0.75%
Price / 1D
$48.165-2.60%
State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
123.77M
Weight
1.09%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$164.1-0.98%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
53.32M
Weight
0.06%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.71-0.74%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
45.06M
Weight
0.31%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.24-0.26%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
39.66M
Weight
0.37%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$211.88-0.79%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
27.33M
Weight
0.12%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.515-0.92%

Continue in GoAI

Research CRSP

research.disclaimer